Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
    • Without Borders
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
    • Article CME
    • Podcast CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 10, 2018; 90 (15 Supplement) April 26, 2018

Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy (S38.001)

Jeffrey Statland, Anthony Amato, Elena Bravver, Craig Campbell, Lauren Elman, Nicholas Johnson, Nanette Joyce, Chafic Karam, John Kissel, Lawrence Korngut, Erin O’Ferrall, Georgios Manousakis, Alan Pestronk, Perry B. Shieh, Rabi Tawil, Ashley Leneus, Barry Miller, Matthew L. Sherman, Chad E. Glasser, Kenneth M. Attie
First published April 9, 2018,
Jeffrey Statland
University of Kansas Medical Center Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anthony Amato
Brigham and Women’s Hospital Boston MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Bravver
Carolinas Healthcare System Neurosciences Institute Charlotte NC United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig Campbell
Children’s Hospital London Health Sciences Centre London ON Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren Elman
University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Johnson
University of Utah Salt Lake City UT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanette Joyce
University of California Davis Medical Center Sacramento CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chafic Karam
Oregon Health and Science University Portland OR United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Kissel
The Ohio State University Columbus OH United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Korngut
University of Calgary Calgary AB Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erin O’Ferrall
Montreal Neurological Institute Montreal QC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Georgios Manousakis
University of Minnesota Minneapolis MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Pestronk
Washington University School of Medicine Saint Louis MO United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Perry B. Shieh
University of California, Los Angeles Los Angeles CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rabi Tawil
University of Rochester School of Medicine Rochester NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Leneus
Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Miller
Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew L. Sherman
Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chad E. Glasser
Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth M. Attie
Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Preliminary Results from a Phase 2 Study to Evaluate ACE-083, a Local Muscle Therapeutic, in Patients with Facioscapulohumeral Muscular Dystrophy (S38.001)
Jeffrey Statland, Anthony Amato, Elena Bravver, Craig Campbell, Lauren Elman, Nicholas Johnson, Nanette Joyce, Chafic Karam, John Kissel, Lawrence Korngut, Erin O’Ferrall, Georgios Manousakis, Alan Pestronk, Perry B. Shieh, Rabi Tawil, Ashley Leneus, Barry Miller, Matthew L. Sherman, Chad E. Glasser, Kenneth M. Attie
Neurology Apr 2018, 90 (15 Supplement) S38.001;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the safety, pharmacodynamics (PD), efficacy, and pharmacokinetics of ACE-083 in patients with facioscapulohumeral muscular dystrophy (FSHD).

Background: ACE-083 is a locally-acting therapeutic based on follistatin that binds myostatin and other muscle regulators. It has been shown to increase muscle mass and force in neuromuscular disease mouse models and to increase muscle mass in healthy volunteers.

Design/Methods: In this study, Part 1 is dose-escalation, open-label, and Part 2 is placebo-controlled. ACE-083 was injected into either the tibialis anterior (TA) or biceps brachii muscle every 3 weeks for 5 doses. Total muscle volume (TMV) and intramuscular fat fraction (FF) were assessed by MRI (Dixon method) on Days 1, 43, 106, and 141. PD assessments include timed motor function tests, gait analysis, and the FSHD-Health Index.

Results: Data were available for this abstract as of Sept 22, 2017 and are shown for patients treated with 150 mg unilaterally into the TA muscle (n=6). Median (range) age was 46.5 yr (42–52), duration of symptoms was 26.5 yr (5–35), and FF was 36.5% (13.6–68.7). Increases in TMV and decreases in FF were seen by Day 43. At Day 106, mean (SD) percent change on the treated side in TMV was 6.7% (8.9) and absolute change in FF (%) was −4.8% (6.4). In the contralateral untreated TA muscle, these changes were −0.5 (7.7) and −0.8 (1.1), respectively. Related adverse events included transient injection site pain/discomfort and myalgia; there were no serious AEs. Dose escalation is ongoing.

Conclusions: ACE-083 was well-tolerated in patients with FSHD and encouraging results were seen for changes in muscle volume and fat fraction in the initial dose cohorts. These preliminary results support further studies of ACE-083 in neuromuscular disorders; current ongoing studies include FSHD and Charcot-Marie-Tooth disease.

Disclosure: Dr. Statland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge, Acceleron, Regeneron, and Sanofi. Dr. Amato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Strongbridge Pharmaceuticals. Dr. Bravver has nothing to disclose. Dr. Campbell has nothing to disclose. Dr. Elman has nothing to disclose. Dr. Johnson has received personal compensation for consulting, serving on a scientific advisory board, speakering, or other activities with AMO Pharma, AveXis and Strongbridge Pharma. Dr. Johnson has received compensation in an editorial capacity for Neurology Genetics. Dr. Johnson has received research support from Biogen Idec, Cytokinetics, AMO Pharma, AveXis and Ionis Pharmaceuticals. Dr. Joyce has nothing to disclose. Dr. Karam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with alnylam, alexion, sanofigenzyme,nufactor, soleohealth, optioncare. Dr. Kissel has received research support from Novartis, Biomarin, Cytokinetics, CSL Behring, Avexis, Ionis Pharmaceuticals, Quintiles, Axelacare. Dr. Korngut has nothing to disclose. Dr. O'Ferrall has nothing to disclose. Dr. Manousakis has nothing to disclose. Dr. Pestronk has nothing to disclose. Dr. Shieh has nothing to disclose. Dr. Tawil has nothing to disclose. Dr. Leneus has nothing to disclose. Dr. Miller has nothing to disclose. Dr. Sherman has nothing to disclose. Dr. Glasser has nothing to disclose. Dr. Attie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Versartis.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when this article is cited
  • Alert me if a correction is posted
  • Alert me when eletters are published
Neurology: 93 (23)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2019 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise